This inventor holds 42 USPTO granted patents and 29 published patent applications and 1 EPO patent, primarily in Ocular Treatments. Top assignees: Presidio Medical, Inc., Tarsus Pharmaceuticals, Inc., Oyster Point Pharma, Inc.. Active years: 2014-2026.
Location History:
- Palo Alto, CA (US) (2014 - 2019)
- Reno, NV (US) (2019 - 2024)
Company Filing History:
10 out of 14 
10 out of 11 
9 out of 20 
Years Active: 2014-2026
Areas of Expertise:
Title: Douglas Michael Ackermann, Jr.: Innovator in Ophthalmic Treatments
Introduction: Douglas Michael Ackermann, Jr. is a prominent inventor based in Reno, NV, known for his significant contributions to the field of ophthalmology. With a remarkable portfolio of 33 patents, Ackermann has focused his research on the development of innovative compositions and methods aimed at treating ophthalmic and dermatologic conditions, particularly blepharitis.
Latest Patents: Among his recent patents, Ackermann has disclosed groundbreaking methods involving isoxazoline parasiticide formulations. These methods provide effective ways to treat or prevent various ophthalmic and dermatologic conditions by topically administering an effective amount of isoxazoline parasiticide or formamidine parasiticide. The formulations include a pharmaceutically acceptable vehicle, enhancing their applicability in clinical settings. His work notably addresses ocular surface conditions like blepharitis, a common ailment impacting eye health.
Career Highlights: Throughout his career, Ackermann has made significant advancements in pharmaceutical formulations aimed at ocular therapies. His expertise has propelled his work in both Oculeve, Inc. and Oyster Point Pharma, Inc., where he has played a vital role in the development of innovative treatments for eye care.
Collaborations: Douglas has collaborated with respected colleagues in the industry, including James Donald Loudin and Bobak Robert Azamian. These partnerships have further enriched his knowledge and insight, influencing his patent developments and innovative approaches to treatment.
Conclusion: Douglas Michael Ackermann, Jr. exemplifies the spirit of innovation within the life sciences, specifically in ophthalmological research. His 33 patents highlight his commitment to enhancing patient care through effective treatments for ocular conditions. With his contributions, Ackermann continues to inspire future advancements in the pharmaceutical field.